52 results on '"Ball, Somedeb"'
Search Results
2. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML
3. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes
4. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion
5. Utilization of serial next-generation sequencing among patients receiving CPX-351 for newly diagnosed acute myeloid leukemia
6. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
7. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials
8. Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians
9. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week
10. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy
11. MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3
12. MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
13. AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen
14. AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia
15. Microparticles in Hematological Malignancies: Role in Coagulopathy and Tumor Pathogenesis
16. MDS-352 Myelodysplastic syndromes with concomitant SF3B1 mutation and deletion of the long arm of chromosome 5
17. Myelodysplastic Syndromes With Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5
18. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
19. Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
20. Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients
21. The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes
22. Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML
23. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
24. Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351
25. A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome
26. Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
27. Heart Failure with Carfilzomib in Patients with Multiple Myeloma: A Meta-analysis of Randomized Controlled Trials
28. Dysautonomia: An Overlooked Neurological Manifestation in a Critically ill COVID-19 Patient
29. Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
30. Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes
31. Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia
32. Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia
33. Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience
34. Extra-axial Chordoma Masquerading as Lung Cancer
35. Primary Extra-axial Chordoma Masquerading as Lung Cancer: Case Report and Review of the Literature
36. COVID-19 INFECTION COMPLICATED BY GUILLAIN-BARRÉ SYNDROME: A CASE REPORT
37. Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen
38. Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
39. Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails
40. Performance of the New Automated Latex Immunoturbidometric Assay in the Diagnosis of Heparin Induced Thrombocytopenia: A Single Institution Experience
41. Effective Implementation of a Structured Protocol for Facilitation of the Judicious Use of Antibody Test for Diagnosis of Heparin Induced Thrombocytopenia
42. Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma
43. Risk of Renal Toxicities with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
44. Risk of Renal Toxicities With Carfilzomib In Patients With Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
45. A Restructured Approach to Diagnosis of Heparin Induced Thrombocytopenia in a Large Tertiary Hospital
46. Risk of Infection with Ibrutinib in Patients with B-Cell Malignancies: A Meta-Analysis of Phase III Randomized Controlled Trials
47. Poster: MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3
48. Poster: MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
49. Poster: AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen
50. Poster: AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.